240 related articles for article (PubMed ID: 32528904)
21. Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.
Ramesh V; Kaushal H; Mishra AK; Singh R; Salotra P
BMC Public Health; 2015 Oct; 15():1092. PubMed ID: 26503551
[TBL] [Abstract][Full Text] [Related]
22. Post kala-azar dermal leishmaniasis in the Indian sub-continent: challenges and strategies for elimination.
Kumar A; Singh VK; Tiwari R; Madhukar P; Rajneesh ; Kumar S; Gautam V; Engwerda C; Sundar S; Kumar R
Front Immunol; 2023; 14():1236952. PubMed ID: 37638047
[TBL] [Abstract][Full Text] [Related]
23. Real-time PCR in detection and quantitation of Leishmania donovani for the diagnosis of Visceral Leishmaniasis patients and the monitoring of their response to treatment.
Hossain F; Ghosh P; Khan MAA; Duthie MS; Vallur AC; Picone A; Howard RF; Reed SG; Mondal D
PLoS One; 2017; 12(9):e0185606. PubMed ID: 28957391
[TBL] [Abstract][Full Text] [Related]
24. In-situ immune profile of polymorphic vs. macular Indian Post Kala-azar dermal leishmaniasis.
Sengupta R; Mukherjee S; Moulik S; Mitra S; Chaudhuri SJ; Das NK; Chatterjee U; Chatterjee M
Int J Parasitol Drugs Drug Resist; 2019 Dec; 11():166-176. PubMed ID: 31542359
[TBL] [Abstract][Full Text] [Related]
25. PKDL--A Silent Parasite Pool for Transmission of Leishmaniasis in Kala-azar Endemic Areas of Malda District, West Bengal, India.
Ganguly S; Saha P; Chatterjee M; Roy S; Ghosh TK; Guha SK; Kundu PK; Bera DK; Basu N; Maji AK
PLoS Negl Trop Dis; 2015; 9(10):e0004138. PubMed ID: 26485704
[TBL] [Abstract][Full Text] [Related]
26. Post-kala-azar dermal leishmaniasis in visceral leishmaniasis-endemic communities in Bihar, India.
Singh RP; Picado A; Alam S; Hasker E; Singh SP; Ostyn B; Chappuis F; Sundar S; Boelaert M
Trop Med Int Health; 2012 Nov; 17(11):1345-8. PubMed ID: 22882665
[TBL] [Abstract][Full Text] [Related]
27. Challenges in the diagnosis of post kala-azar dermal leishmaniasis.
Salotra P; Singh R
Indian J Med Res; 2006 Mar; 123(3):295-310. PubMed ID: 16778312
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology of Post-Kala-azar Dermal Leishmaniasis.
Ghosh P; Roy P; Chaudhuri SJ; Das NK
Indian J Dermatol; 2021; 66(1):12-23. PubMed ID: 33911289
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of a rapid immunochromatographic test for diagnosis of kala-azar & post kala-azar dermal leishmaniasis at a tertiary care centre of north India.
Mathur P; Samantaray J; Chauhan NK
Indian J Med Res; 2005 Dec; 122(6):485-90. PubMed ID: 16517998
[TBL] [Abstract][Full Text] [Related]
30. Advanced case of PKDL due to delayed treatment: A rare case report.
Topno RK; Rabi Das VN; Kumar M; Madhukar M; Pandey K; Verma N; Agrawal K; Lal CS; Siddiqui NA; Bimal S; Das P
PLoS Negl Trop Dis; 2020 Mar; 14(3):e0008052. PubMed ID: 32203500
[TBL] [Abstract][Full Text] [Related]
31. The immunology of post-kala-azar dermal leishmaniasis (PKDL).
Zijlstra EE
Parasit Vectors; 2016 Aug; 9(1):464. PubMed ID: 27553063
[TBL] [Abstract][Full Text] [Related]
32. Post-kala-azar dermal leishmaniasis--an overview.
Ganguly S; Das NK; Barbhuiya JN; Chatterjee M
Int J Dermatol; 2010 Aug; 49(8):921-31. PubMed ID: 21128917
[TBL] [Abstract][Full Text] [Related]
33. IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India.
Saha S; Mondal S; Ravindran R; Bhowmick S; Modak D; Mallick S; Rahman M; Kar S; Goswami R; Guha SK; Pramanik N; Saha B; Ali N
J Immunol; 2007 Oct; 179(8):5592-603. PubMed ID: 17911647
[TBL] [Abstract][Full Text] [Related]
34. Visceral Leishmaniasis-HIV Coinfection as a Predictor of Increased
Cloots K; Marino P; Burza S; Gill N; Boelaert M; Hasker E
Front Cell Infect Microbiol; 2021; 11():604117. PubMed ID: 33777831
[TBL] [Abstract][Full Text] [Related]
35. Post kala-azar dermal leishmaniasis: A threat to elimination program.
Gedda MR; Singh B; Kumar D; Singh AK; Madhukar P; Upadhyay S; Singh OP; Sundar S
PLoS Negl Trop Dis; 2020 Jul; 14(7):e0008221. PubMed ID: 32614818
[TBL] [Abstract][Full Text] [Related]
36. Liposomal amphotericin B is more effective in polymorphic lesions of post kala-azar dermal leishmaniasis.
Moulik S; Sengupta R; Ghosh MK; Das NK; Saha B; Chatterjee M
Indian J Dermatol Venereol Leprol; 2022; 88(2):201-206. PubMed ID: 33969651
[TBL] [Abstract][Full Text] [Related]
37. Molecular Tracking of the
Moulik S; Sengupta S; Chatterjee M
Front Cell Infect Microbiol; 2021; 11():623437. PubMed ID: 33692966
[TBL] [Abstract][Full Text] [Related]
38. Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL).
Katara GK; Ansari NA; Singh A; Ramesh V; Salotra P
PLoS Negl Trop Dis; 2012; 6(6):e1703. PubMed ID: 22724038
[TBL] [Abstract][Full Text] [Related]
39. Dermal microdialysis: A method to determine drug levels in the skin of patients with Post kala-azar dermal leishmaniasis (PKDL).
Wijnant GJ; Moulik S; Chatterjee K; Das NK; de la Flor R; Van Bocxlaer K; Croft SL; Chatterjee M
Exp Parasitol; 2024 Feb; 257():108687. PubMed ID: 38114040
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of serological markers to monitor the disease status of Indian post kala-azar dermal leishmaniasis.
Mukhopadhyay D; Das NK; De Sarkar S; Manna A; Ganguly DN; Barbhuiya JN; Maitra AK; Hazra A; Chatterjee M
Trans R Soc Trop Med Hyg; 2012 Nov; 106(11):668-76. PubMed ID: 22920931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
